• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$50.49 -$0.13 (-0.26%)

REAL-TIME: Last trade at

Gilead Sciences

NASDAQ:GILD

7 Biotech Stocks to Add to Your Portfolio

Gilead Files European Marketing Application for Boosting Agent Cobicistat

Gilead files European Marketing Application for boosting agent cobicistat

Gilead Files European Marketing Application for Boosting Agent Cobicistat

Gilead Sciences Inc.: Strong Growth At A Low Price

Gilead Sciences’ HIV Drugs Clear a Hurdle

Gilead likey to remain dominant in HIV treatment for some time, says Wells Fargo

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases

Two Positive Advisory Committee Votes, Quad on Track for August Approval as Expected

Gilead Sciences, Inc.' HIV Quad Pill Wins Backing From FDA Advisers

A Health Care Fortnight for the Record Books

Research Reports for Chesapeake Energy, Bank of America, Ford, Ciena, Nuance Communications, and Gilead Sciences

Gilead Quad approval will be important, says RW Baird

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV

Gilead Sciences HIV Drug Quad Gets FDA Panel Backing

Gilead Sciences (GILD) Gets FDA Advisory Committee Support of Quad HIV-1 Treatment

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV

Gilead Sciences (GILD) Gets FDA Committee Support for Truvada

FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV

FDA Anti-Viral Drugs Advisory Committee to hold a meeting

AIDS Healthcare Foundation to host a teleconference

Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16

Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16

Vertex Is the Next Gilead Sciences or Alexion

The FDA Pediatric Advisory Committee to hold a meeting

Goldman Sachs Positive On Gilead Sciences (GILD) Ahead of Quad AdCom

Lack of data on Bristol-Myers' hep C treatment raises red flag, The Street says

Deutsche Bank's biotech analyst to hold a conference call

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May [UPDATE]

Pharmacyclics shares should be bought on any weakness, says RBC Capital

Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8

Gilead starts Phase 3 trial evaluating GS-1101 for Leukemia treatment

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia

Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8

AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences

Gilead Sciences Looks For Hepatitis C Cure

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May

Merck Pins Hopes On Product Pipeline

Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Raising Numbers on Recent Progress in HCV

See More Articles...